Anti-CEACAM1 antibody and use thereof
US11332528B2 · kind B2 · utility
0Cited by
1References
32Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 23, 2018 |
| Grant date | May 17, 2022 |
| Priority date | — |
| Expiry date | Aug 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.